- Home
- ISRG vs NVO Comparison
ISRG vs NVO Comparison
Compare ISRG & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | NVO |
|---|---|---|
| Founded | 1995 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.8B | 197.4B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | ISRG | NVO |
|---|---|---|
| Price | $422.06 | $43.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 11 |
| Target Price | ★ $591.32 | $51.00 |
| AVG Volume (30 Days) | 2.2M | ★ 10.9M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | ★ $10,064,700,000.00 | N/A |
| Revenue This Year | $16.64 | N/A |
| Revenue Next Year | $13.91 | $3.70 |
| P/E Ratio | $183.65 | ★ $13.60 |
| Revenue Growth | ★ 20.51 | N/A |
| 52 Week Low | $396.68 | $35.12 |
| 52 Week High | $603.88 | $81.44 |
Technical Indicators
Market Signals| Indicator | ISRG | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 46.75 |
| Support Level | N/A | $35.49 |
| Resistance Level | $453.63 | $50.30 |
| Average True Range (ATR) | 12.55 | 1.15 |
| MACD | -0.50 | -0.45 |
| Stochastic Oscillator | 46.16 | 27.11 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.